AN IMMUNOASSAY-BASED POINT OF CARE TEST KIT FOR RAPID, INEXPENSIVE AND EFFORTLESS DETECTION OF URINARY TRACT INFECTIONS

Informations projet

RAPID UTI

N° de convention de subvention: 101114063

DOI

10.3030/101114063

Projet clôturé

Date de signature de la CE 7 Juin 2023

Date de début 1 Juillet 2023

Date de fin 30 Juin 2024

Financé au titre de

• European innovation ecosystems

Coût total

Aucune donnée

Contribution de l’UE

€ 75 000,00

Coordonné par

NANOMED DIAGNOSTIC BIYOTEKNOLOJI ARGE LIMITED SIRKETI
Türkiye

Periodic Reporting for period 1 - RAPID UTI (AN IMMUNOASSAY-BASED POINT OF CARE TEST KIT FOR RAPID, INEXPENSIVE AND EFFORTLESS DETECTION OF URINARY TRACT INFECTIONS)

Période du rapport: 2023-07-01 au 2024-06-30

Résumé du contexte et des objectifs généraux du projet

In today’s rapidly evolving healthcare landscape, there is a crucial need for efficient and accurate diagnostic tools. Urinary tract infections (UTIs) pose a widespread health challenge, often requiring prompt and precise detection to avoid severe complications. Nanomed Diagnostic tackled this issue by developing the RAPID UTI diagnostic kit, a cutting-edge tool designed to transform UTI diagnosis and management.

UTIs are common but can lead to serious health problems if not diagnosed and treated swiftly. Traditional methods can be time-consuming and resource-intensive, creating a need for a faster, more accessible solution. Nanomed Diagnostic's goal was to create a diagnostic kit that delivers rapid, accurate results, improving patient care and streamlining healthcare processes. Key objectives included:

Clinical Validation: Conducting thorough clinical trials to confirm the kit’s accuracy and reliability.
Regulatory Compliance: Securing CE and ISO 9001 certifications to meet international standards.
Market Expansion: Establishing entry into European and international markets through strategic partnerships.
Increased Visibility: Enhancing market presence by participating in international conferences and engaging with stakeholders.
Expected Impact

The RAPID UTI kit aims to:

Enhance Diagnostic Efficiency: Offer rapid, precise results to expedite diagnosis and treatment, improving patient outcomes.
Improve Accessibility: Ensure usability in diverse healthcare settings, including remote areas, thus extending its reach.
Support Healthcare Professionals: Provide reliable data to aid in informed decision-making and care quality.
Expand Global Reach: Utilize certifications and distribution networks to make the kit widely available, addressing global diagnostic needs.
The project underscores the importance of integrating advanced technology with practical healthcare solutions, setting a benchmark for future innovations. Supported by EU funding, it represents a significant advancement in healthcare, benefiting patients, providers, and the broader system.

Travail effectué depuis le début du projet jusqu’à la fin de la période considérée dans le rapport et principaux résultats atteints jusqu’à présent

Design and Engineering: Creation of a user-friendly tool integrating advanced technology for rapid and accurate results. This involved hardware and software development.
Prototype Testing: Multiple prototypes were tested to refine design and functionality, ensuring the final product met technical specifications and performance standards.
Clinical Trials: The kit was rigorously tested in clinical settings to assess its sensitivity, specificity, and accuracy against standard methods.
Data Analysis: Clinical data confirmed the kit’s reliability and effectiveness, validating it as a viable diagnostic alternative.
CE Certification: The kit met EU safety and performance standards, allowing it to be marketed in European countries.
ISO 9001 Certification: Quality management processes were certified, ensuring adherence to international standards.
Facility Construction: A state-of-the-art production facility in Şanlıurfa Teknokent, Turkey, was established for large-scale manufacturing.
Licensing and Certification: The facility obtained necessary licenses and certifications, including CE and ISO 9001.
Market Entry Strategy: Preparations included negotiations with European distributors and addressing regulatory requirements for other regions, including the U.S.
FDA Certification Efforts: Initiated the process to obtain FDA certification for U.S. market entry.

Outcomes of the Action The project achieved:
Validated Diagnostic Tool: The RAPID UTI kit is validated, certified, and capable of rapid and accurate UTI detection.
Regulatory Certifications: CE and ISO 9001 certifications were obtained.
Operational Production Facility: A licensed and certified facility supports large-scale manufacturing.
Market Expansion Preparedness: Groundwork for global distribution, including FDA certification efforts, is underway.

Progrès au-delà de l’état des connaissances et impact potentiel prévu (y compris l’impact socio-économique et les conséquences sociétales plus larges du projet jusqu’à présent)

The RAPID UTI project has achieved significant milestones, laying a strong foundation for further advancements:

Validated Diagnostic Kit: The RAPID UTI diagnostic kit has undergone extensive clinical validation, proving its high accuracy and reliability. It is CE certified and complies with ISO 9001 standards, making it ready for distribution in European markets.
Operational Production Facility: A cutting-edge production facility has been established in Şanlıurfa Teknokent, Turkey. This facility is fully operational, capable of large-scale production, and adheres to all necessary regulatory and quality standards.
Regulatory Preparation: Significant progress has been made towards obtaining FDA certification, crucial for entering the U.S. market. This paves the way for global distribution and market expansion.
Market Expansion Readiness: Strategic distributor negotiations and regulatory compliance efforts have set the stage for expanding into new markets, particularly in Europe.

Potential Impacts

Improved Patient Outcomes: Rapid and accurate UTI detection will lead to quicker diagnosis and treatment, improving patient outcomes and reducing untreated infections.
Enhanced Diagnostic Efficiency: The kit will streamline diagnostic processes, making them more efficient and potentially lowering healthcare costs.
Market Growth: With certifications and an operational facility, the kit is positioned to capture significant market share in Europe and beyond, contributing to advancements in diagnostic technology.
Global Expansion: Efforts to secure FDA certification and establish market presence in the U.S. will enhance global reach and impact.

To ensure continued success, the following needs must be addressed:

Further Research and Development: Ongoing research is needed to refine the technology, explore new applications, and maintain advancement.
Demonstration and Validation: Additional studies in diverse settings will validate the kit’s performance and build stakeholder confidence.
Access to Markets and Finance: Securing funding and investment will be crucial for scaling operations and supporting R&D.
Commercialisation: Effective marketing and distribution strategies will maximize market penetration and commercial success.
IPR Support: Protecting intellectual property through patents and legal mechanisms is essential for maintaining a competitive edge.
Internationalisation: Expanding into new international markets requires navigating regulatory environments and establishing local partnerships.
Supportive Regulatory and Standardisation Framework: Adhering to regional regulatory requirements and standards will ensure smooth market entry and compliance.